Neuropathic Pain Studies: Patient Selection, Study Design, and Clinical Trial Challenges


Treatment of neuropathic pain has been a challenge for drug developers for years. Opioids show limited efficacy and are subject to abuse. Tricyclic antidepressants, long considered first-line therapy, have been hampered by side effects and are still effective in only about one-third of patients.

More recently, serotonin-norepinephrine reuptake inhibitors and some anticonvulsants have been approved for painful diabetic neuropathy, fibromyalgia, and other chronic conditions, but they are even less effective than tricyclic antidepressants in most patients. New chemical entities with novel mechanisms of action continue to be studied for these disorders, especially with the recent focus on non-opioid analgesic alternatives.

Drug developers are still searching for effective therapies for neuropathic pain conditions to address this underserved patient population. This webcast will describe the most common neuropathic pain conditions, unique protocol design features required for these varying afflictions, and challenges facing researchers during execution of these clinical studies.

Key Learning Objectives:

  • What the most common neuropathic pain conditions are
  • The unique protocol requirements for neuropathic pain trials
  • What the current challenges in neuropathic pain trials are and how to best overcome them


Title: Neuropathic Pain Studies: Patient Selection, Study Design, and Clinical Trial Challenges

Date: Tuesday, November 6, 2018

Time: 11am EDT | 10am CDT | 4pm BST | 5pm CEST

Duration: 60 minutes

Featured Speakers:

  • Michael Kuss, Vice President, Clinical Development Services, Analgesia, Premier Research
  • Scott Millard, Executive Director, Strategic Development, Analgesia, Premier Research
  • Dr. Michael H. Skinner, MD, PharmDExecutive Director, Medical Affairs and Strategic Consulting, Premier Research
Phone Us Now
Email Us Now